© Reuters. ARCHIVE PHOTO: An employee works on a vaccine based on the monkeypox vaccine that has already been developed by the Bavarian Nordic vaccine company in a company laboratory in Martinsried, near Munich, Germany, on 24 May 2022. REUTERS / Lukas Barth / File Pho
(Reuters) – Danish biotechnology company Bavarian Nordic revised its annual guide for the second time on Monday after signing supply contracts with several undisclosed countries for its Imvanex vaccine.
Bavarian Nordic said vaccine deliveries would begin immediately and added that it was in talks with more countries regarding the supply of vaccines.
“We are pleased to help more countries with the supply of vaccines as we continue our dialogues with other governments to make vaccines available as soon as possible to mitigate the situation,” CEO Paul Chaplin said in a statement.
Bavarian now expects revenue of 2022 billion and 1,500 billion kroner ($ 202.93 million and $ 217.43 million) by 2022, more than previous estimates of 1.3 billion to 1.5 billion. .
The company also raised its earnings expectations before interest, taxes and amortization (EBITDA) to a loss of between 900 million and 1.1 billion kroner, more than the previous target of losses of between 1,000 and 1,200 millions of crowns.
Smallpox is an infectious disease that is usually mild and is endemic to parts of West and Central Africa. World health authorities have been monitoring more than 200 suspected and confirmed cases of viral infection in 19 countries since early May.
The European Union announced last week that it was in talks to buy the Bavarian Nordic vaccine. The vaccine has the official European approval for smallpox, although doctors may prescribe it off the label for smallpox.